IVERIC bio Inc. buy melinda
Startpreis
03.11.18
/
50%
2,07 €
Kursziel
29.11.18
2,16 €
Rendite (%)
-21,74 %
Endpreis
29.11.18
1,62 €
Zusammenfassung
Diese Einschätzung wurde am 29.11.18 mit einem Endkurs von 1,62 € beendet. Die Einschätzung zu IVERIC bio Inc. enttäuschte mit einer Rendite von -21,74 %. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| IVERIC bio Inc. | - | - | - | - |
| iShares Core DAX® | -0,92 % | -1,08 % | 12,16 % | 16,80 % |
| iShares Nasdaq 100 | 0,37 % | -0,56 % | 38,62 % | 49,37 % |
| iShares Nikkei 225® | 2,22 % | -2,83 % | 19,01 % | 4,64 % |
| iShares S&P 500 | -0,03 % | -0,79 % | 28,48 % | 42,48 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion IVERIC bio Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 26/02 Publication de résultats
Develops novel therapeutics to treat diseases of the eye
Ophthotech Corp. is a biopharmaceutical company,which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.
Its product candidates include Zimura and Gene Therapy.
The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.
Ophthotech Corp. is a biopharmaceutical company,which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.
Its product candidates include Zimura and Gene Therapy.
The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.
Nombre d'employés : 38 personnes.
(Vom Mitglied beendet)